FDA DEVICE FACTS
COBAS EGFR MUTATION TEST V2
Roche
Verified FDA Record identity for medical-device development research. This overview uses only fields stated in the FDA Record and is not a Device Description.医療機器開発の調査用に、確認済みの FDA Record の識別情報を示しています。この概要は FDA Record に記載された項目だけによるもので、機器説明ではありません。
Indications for use
The cobas ® EGFR Mutation Test v2 is a real-time PCR test for the qualitative detection of defined mutations of the epidermal growth factor receptor (EGFR) gene in DNA derived from formalin-fixed paraffin-embedded tumor tissue (FFPET) from non-small
cell lung cancer (NSCLC) patients. The test is intended to aid in identifying patients with NSCLC whose tumors have defined EGFR mutations and for whom safety and efficacy of a drug have been established as follows:
Tarceva® (erlotinib) Exon 19 deletions and L858R Tagrisso® (osimertinib) T790M
Drug safety and efficacy have not been established for the following EGFR mutations also detected by the cobas® EGFR Mutation Test v2:
Tarceva® (erlotinib) G719X, exon 20 insertions, T790M, S768I and L861Q Tagrisso® (osimertinib) G719X, exon 19 deletions, L858R, exon 20 insertions, S768I, and L861Q
For manual sample preparation, FFPET specimens are processed using the cobas ® DNA Sample Preparation Kit and the cobas z 480 analyzer is used for automated amplification and detection.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。